Research Article
Treatment Adherence in Inflammatory Bowel Disease Patients from Argentina: A Multicenter Study
Table 2
Comparative use of chronic medications between enrolled UC/IBDU and CD patients.
| | UC/IBDU (), % | CD (), % | OR (CI95%) | |
| | Oral 5-ASA | 80.31 (359/447) | 85.93 (116/135) | 0.67 (0.39-1.14) | 0.1 | | Rectal 5-ASA | 22.37 (100/447) | 16.3 (22/135) | 1.48 (0.89-2.46) | 0.1 | | Oral budesonide | 3.36 (15/447) | 2.22 (3/135) | 1.52 (0.43-5.36) | 0.5 | | Thiopurines | 35.8 (160/447) | 56.29 (76/135) | 0.69 (0.45-1.05) | 0.08 | | Methotrexate | 0.89 (4/447) | 0.74 (1/135) | 1.21 (0.13-10.93) | 0.8 | | Prednisone | 8.72 (39/447) | 11.85 (16/135) | 0.71 (0.38-1.32) | 0.2 | | Biologics (all) | 24.83 (111/447) | 33.33 (45/135) | 0.69 (0.45-1) | 0.06 | | Infliximab | 9.17 (41/447) | 11.11 (15/135) | 0.8 (0.43-1.51) | 0.5 | | Adalimumab | 13.65 (61/447) | 19.26 (26/135) | 0.66 (0.39-1.1) | 0.1 | | Vedolizumab | 0.89 (4/447) | 1.48 (2/135) | 0.6 (0.1-3.32) | 0.5 | | Certolizumab | 0 | 1.37 (2/135) | N/A | 0.4 | | Golimumab | 1.12 (5/447) | 0 | N/A | 0.1 |
|
|
UC: ulcerative colitis; CD: Crohn’s disease; IBDU: inflammatory bowel disease unclassified; OR: odds ratio; CI: confidence interval; 5-ASA: 5-aminosalicylates.
|
